MLTX Q4 2024 Earnings — MoonLake Immunotherapeutics Revenue & Financial Results | Market Cap Arena

MLTXMoonLake Immunotherapeutics

$1B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$50M

Net Income

-$46M

EPS (Diluted)

$-0.72

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$48M

Free Cash Flow

-$49M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$478M

Total Liabilities

$25M

Stockholders' Equity

$447M

Cash & Equivalents

$180M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$50M	-$15M	-229.9%
Net Income	-$46M	-$7M	-513.2%